What is the lead time for production?

Lead time is within 15 workdays during off-season, and 1-3 months during peak season.

Does the machine support FDA 21 CFR Part 11?

Yes, it features electronic records and signatures in compliance with FDA 21 CFR Part 11.

Gzpl-680 Series Sided High-Speed Rotary Pill Making Equipment

Name: Gzpl-680 Series Sided High-Speed Rotary Pill Making Equipment
Brand: Shanghai Pharmaceutical Machinery Co., Ltd.
SKU: 766744665

Shanghai, ChinaShanghai Pharmaceutical Machinery Co., Ltd.

Negotiable

1 Set

Product profile

Warranty

1 Year

Weight

4800kg

Rated Power

14kw

Model NO.

GZPL-680

Noise

Less Than 85 Dba

Max.Mian Compression Force

100kn

Max. Tablet Thickness

8.5mm

Type

Preparation Machinery

Finished Dosage Form

Tablet

Precision

High Precision

Certification

CE, GMP, ISO

Voltage

380V

Computerized

Customized

Condition

New

Transport Package

Standard Export Wooden Cases

Specification

GMP and FDA.

Trademark

SPM

Origin

China

HS Code

8479820090

Production Capacity

758000tablets/H

Key features

GMP & FDA Compliance: Meets GMP and FDA standards with electronic records and signatures per 21 CFR Part 11.

High Precision Control: Servo motor control with interchangeable turret for high-precision tablet compression.

Customization Options: Offers full, minor, and flexible customization from samples or designs.

Advanced Technology: Independently developed with leading domestic design and control technology.

Quality Assurance: 100% inspection for finished products including visual and function checks.

Multi-Certification: Certified by CE, GMP, ISO, and SGS for global market compliance.

Company profile

Experienced TeamExhibition ExperienceImporters and ExportersLow MOQ

Shanghai Pharmaceutical Machinery Co., Ltd.

Shanghai, China

CertifiedBusiness Type: Manufacturer/Factory & Trading Company CertifiedCustomization Options: Customization from Samples, Customization from Designs, etc. CertifiedExport Year: 20 Years CertifiedNearest Port: Shanghai PortAverage Response Time: ≤7.79h CertifiedTerms of Payment: T/T, LC, PayPal, etc.

AI-Powered supplier vetting

SummaryThe supplier is identified as a Shanghai-based combined trading company with listed pharmaceutical equipment products and machining-related facilities. It reports extensive customization, R&D activity with new products in the past year, export experience of 20 years, and exports representing 90% of total sales. After-sales support includes repair services and overseas agents or branches, but no overseas warehouse or showroom. Finished-product inspection instructions are reportedly available and uniformly followed. The supplier does not provide ODM services, lacks an available SDK, and does not provide OEM services for well-known brands. Evidence is insufficient to verify certifications, detailed financial credibility, production scale, or named customer cases.

After-Sales capabilityThe supplier reports repair as an overseas service offering and states that it can provide services through overseas agents or branches. However, it has no overseas warehouse or showroom, so the evidence supports some service access but not comprehensive overseas infrastructure.

R&D capabilityThe supplier reports R&D capability and states that it launched new products during the past year. It does not have an available SDK and does not provide ODM services, but these limitations do not negate the explicit evidence of recent product development.

Production capacityThe supplier lists machining centers, CNC and milling equipment, provides a broad pharmaceutical-equipment product range, and reports a finished-product inspection method with instructions that are uniformly followed. However, the supplied data does not quantify production capacity, output, or manufacturing ownership, so production strength is only partially evidenced.

Customization capabilityBoth R&D and design-service records explicitly list customization from samples, designs, full customization, minor customization, and flexible customization. This is direct evidence of a broad customization offering.